These are exciting times for cancer immunotherapy. After many years of disappointing
results, the tide has finally changed and immunotherapy has become a clinically validated …

Recent clinical data have emphatically shown the capacity of our immune systems to
eradicate even advanced cancers. Although oncolytic viruses (OVs) were originally …

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill
infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells …

Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding
therapeutic option for a wide range of human malignancies. Despite the ongoing progress of …

Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a
promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted …

This review discusses current clinical advancements in oncolytic viral therapy, with a focus
on the viral platforms approved for clinical use and highlights the benefits each platform …

Chimeric antigen receptor (CAR) T-cell therapy is an encouraging and fast-growing platform
used for the treatment of various types of tumors in human body. Despite the recent success …

Highlights•Oncolytic viruses (OVs) can modulate tumour microenvironment (TME) towards
less immunosuppressive phenotype and induce anti-cancer immunity.•OVs can be used as …

Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in
unprecedented rates of long-lasting complete responses in patients with leukemia and …

Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical
models and in early phase clinical trials. Reovirus has direct oncolytic activity against a …